CO-ALEPH-OBJECTS
Aleph Objects, Inc., a leader in professional desktop 3D printers, will launch its 3D printing business into the European market today. Building on the LulzBot 3D Printer line’s reputation as the leader in reliability and ease of use, the expansion will address the specific needs of European customers and resellers. The company’s new European headquarters, Aleph Objects Netherlands B.V., is located in vibrant Rotterdam, Netherlands. To continue to build future business opportunities throughout Europe, a new holding company, Aleph Objects Europe Holding B.V., was established as well.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190507005980/en/
A Legacy of Award-Winning Reliability
With over 80 awards in 2018, Aleph Objects is rapidly expanding into the professional and industrial 3D printing market. LulzBot 3D Printers are favored by all branches of the US Military for their reliability and dependable performance in the most extreme environments. The company relies on hundreds of its own printers working 24/7 to manufacture production-grade parts for more printers, having printed millions of parts. Automotive racing teams also prefer LulzBot 3D Printers for their unparalleled print quality, building end-use products straight from the print bed.
A Projection for Exponential Growth
“European revenue growth in 2019 alone is expected to reach triple digits, with a projected overall representation of more than 30% of our future business,” said Grant Flaharty, Aleph Objects CEO and President. The European expansion follows the recent introduction of two new 3D printers this year.
The LulzBot TAZ Pro , Aleph Objects’ first industrial desktop 3D printer, provides multi-material and soluble 3D printing for large prototypes, manufacturing aids, and print-on-demand parts.
The LulzBot TAZ Workhorse , released earlier this month, builds on the workhorse reputation of the LulzBot TAZ line. It includes a larger build volume, a strengthened design, and new automatic calibration features.
A Trusted Local Business Presence
Located in Rotterdam, Netherlands, near Brussels and The Hague, known as the EU’s administrative heart, the new Aleph Objects office is strategically situated at the gateway to Europe. The local physical presence will facilitate Aleph Objects’ relationships with customers and resellers, providing a place for product demonstrations, support, and consulting.
The entrepreneurial spirit and real-life testing of engineering in this urbanized delta are a great fit with collaborative engineering solutions of LulzBot 3D Printers based on Free Software, Libre Innovation, and Open Source Hardware.
About Aleph Objects, Inc.
Aleph Objects, Inc. is the Colorado-based designer and manufacturer of the award-winning line of LulzBot® 3D Printers. LulzBot is a trusted brand in Automotive, Consumer Products, Aerospace/Defense, Medical, and Education industries around the globe. Aleph Objects’ core company values of Free Software, Libre Innovation, and Open Source Hardware enable users to uniquely modify both software and hardware to bring their imagination to life. For more information, visit www.LulzBot.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190507005980/en/
Contact:
Hob Wubbena, Vice President +1-970-377-1111, Ext. 617 or Press Contact: press@lulzbot.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom